Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA recommends extension of therapeutic indications for teclistamab
Дата публикации: 11-09-2026 07:09:00

New indication concerns a combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Epcoritamab08.0424-07-2026
2EMA recommends extension of therapeutic indications for sacituzumab govitecan011.118-09-2026
3EMA Recommends Extension of Therapeutic Indications for Cetuximab011.314-08-2026
4EMA Recommends Extension of Therapeutic Indications for Serplulimab013.8831-07-2026
5Daraxonrasib shows antitumour activity in patients with previously treated metastatic RAS-mutated NSCLC015.8810-09-2026
6U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma06.4413-07-2026
7FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer014.7923-09-2026
8Azacitidine-venetoclax prolongs EFS over induction chemotherapy among induction-eligible patients with AML022.514-09-2026
9Perioperative durvalumab plus FLOT improves OS in patients with resectable gastric or GEJ adenocarcinoma09.2215-09-2026
10STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more08.3631-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.36. Источник: www.esmo.org.